Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context.

Alexis Holman, Daniel J Kruger, Philippe Lucas, Kaye Ong, Rachel S Bergmans, Kevin F Boehnke
{"title":"Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context.","authors":"Alexis Holman, Daniel J Kruger, Philippe Lucas, Kaye Ong, Rachel S Bergmans, Kevin F Boehnke","doi":"10.1186/s42238-022-00141-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients use medical cannabis for a wide array of illnesses and symptoms, and many substitute cannabis for pharmaceuticals. This substitution often occurs without physician oversight, raising patient safety concerns. We aimed to characterize substitution and doctor-patient communication patterns in Canada, where there is a mature market and national regulatory system for medical cannabis.</p><p><strong>Methods: </strong>We conducted an anonymous, cross-sectional online survey in May 2021 for seven days with adult Canadian federally-authorized medical cannabis patients (N = 2697) registered with two global cannabis companies to evaluate patient perceptions of Primary Care Provider (PCP) knowledge of medical cannabis and communication regarding medical cannabis with PCPs, including PCP authorization of licensure and substitution of cannabis for other medications.</p><p><strong>Results: </strong>Most participants (62.7%, n = 1390) obtained medical cannabis authorization from their PCP. Of those who spoke with their PCP about medical cannabis (82.2%, n = 2217), 38.6% (n = 857) reported that their PCP had \"very good\" or \"excellent\" knowledge of medical cannabis and, on average, were moderately confident in their PCP's ability to integrate medical cannabis into treatment. Participants generally reported higher ratings for secondary care providers, with 82.8% (n = 808) of participants rating their secondary care provider's knowledge about medical cannabis as \"very good\" or \"excellent.\" Overall, 47.1% (n = 1269) of participants reported substituting cannabis for pharmaceuticals or other substances (e.g., alcohol, tobacco/nicotine). Of these, 31.3% (n = 397) reported a delay in informing their PCP of up to 6 months or more, and 34.8% (n = 441) reported that their PCP was still not aware of their substitution. Older, female participants had higher odds of disclosing cannabis substitution to their PCPs.</p><p><strong>Conclusion: </strong>Most of the surveyed Canadian medical cannabis patients considered their PCPs knowledgeable about cannabis and were confident in their PCPs' ability to integrate cannabis into treatment plans. However, many surveyed patients substituted cannabis for other medications without consulting their PCPs. These results suggest a lack of integration between mainstream healthcare and medical cannabis that may be improved through physician education and clinical experience.</p>","PeriodicalId":15172,"journal":{"name":"Journal of Cannabis Research","volume":"41 1","pages":"32"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195481/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cannabis Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-022-00141-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients use medical cannabis for a wide array of illnesses and symptoms, and many substitute cannabis for pharmaceuticals. This substitution often occurs without physician oversight, raising patient safety concerns. We aimed to characterize substitution and doctor-patient communication patterns in Canada, where there is a mature market and national regulatory system for medical cannabis.

Methods: We conducted an anonymous, cross-sectional online survey in May 2021 for seven days with adult Canadian federally-authorized medical cannabis patients (N = 2697) registered with two global cannabis companies to evaluate patient perceptions of Primary Care Provider (PCP) knowledge of medical cannabis and communication regarding medical cannabis with PCPs, including PCP authorization of licensure and substitution of cannabis for other medications.

Results: Most participants (62.7%, n = 1390) obtained medical cannabis authorization from their PCP. Of those who spoke with their PCP about medical cannabis (82.2%, n = 2217), 38.6% (n = 857) reported that their PCP had "very good" or "excellent" knowledge of medical cannabis and, on average, were moderately confident in their PCP's ability to integrate medical cannabis into treatment. Participants generally reported higher ratings for secondary care providers, with 82.8% (n = 808) of participants rating their secondary care provider's knowledge about medical cannabis as "very good" or "excellent." Overall, 47.1% (n = 1269) of participants reported substituting cannabis for pharmaceuticals or other substances (e.g., alcohol, tobacco/nicotine). Of these, 31.3% (n = 397) reported a delay in informing their PCP of up to 6 months or more, and 34.8% (n = 441) reported that their PCP was still not aware of their substitution. Older, female participants had higher odds of disclosing cannabis substitution to their PCPs.

Conclusion: Most of the surveyed Canadian medical cannabis patients considered their PCPs knowledgeable about cannabis and were confident in their PCPs' ability to integrate cannabis into treatment plans. However, many surveyed patients substituted cannabis for other medications without consulting their PCPs. These results suggest a lack of integration between mainstream healthcare and medical cannabis that may be improved through physician education and clinical experience.

医疗保健提供者和医用大麻患者关于转诊和药物替代的沟通:加拿大的情况。
背景:患者使用医用大麻治疗各种各样的疾病和症状,许多人用大麻代替药物。这种替代经常在没有医生监督的情况下发生,引起了患者的安全担忧。我们的目的是描述加拿大的替代和医患沟通模式,因为加拿大有成熟的医用大麻市场和国家监管体系。方法:我们于2021年5月对在两家全球大麻公司注册的加拿大联邦授权的成年医用大麻患者(N = 2697)进行了一项为期7天的匿名横断面在线调查,以评估患者对初级保健提供者(PCP)对医用大麻的知识的看法,以及与PCP就医用大麻的沟通,包括PCP授权许可和大麻替代其他药物。结果:大多数参与者(62.7%,n = 1390)从他们的PCP获得医用大麻授权。在那些与PCP谈论医用大麻的人中(82.2%,n = 2217), 38.6% (n = 857)报告说,他们的PCP对医用大麻有“非常好”或“优秀”的了解,平均而言,他们对PCP将医用大麻纳入治疗的能力有适度的信心。参与者普遍报告二级保健提供者的评分较高,82.8% (n = 808)的参与者将其二级保健提供者关于医用大麻的知识评为“非常好”或“优秀”。总体而言,47.1% (n = 1269)的参与者报告用大麻代替药品或其他物质(如酒精、烟草/尼古丁)。其中,31.3% (n = 397)报告延迟通知PCP长达6个月或更长时间,34.8% (n = 441)报告他们的PCP仍然不知道他们的替代品。年龄较大的女性参与者向他们的pcp透露大麻替代品的几率更高。结论:大多数接受调查的加拿大医用大麻患者认为他们的pcp了解大麻,并对他们的pcp将大麻纳入治疗计划的能力充满信心。然而,许多接受调查的患者在没有咨询他们的pcp的情况下用大麻代替其他药物。这些结果表明,主流医疗保健和医用大麻之间缺乏整合,可以通过医生教育和临床经验加以改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书